Status:
ACTIVE_NOT_RECRUITING
MR Antagonist and LSD1
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Hypertension
Mineralocorticoid Excess
Eligibility:
All Genders
17+ years
Phase:
PHASE4
Brief Summary
Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investi...
Detailed Description
This proof-of-principle physiologic study in hypertensive Black LSD1 risk allele carriers testing the hypothesis that reductions in blood pressure will be greater with a genetically-driven anti-hypert...
Eligibility Criteria
Inclusion
- untreated as well as currently treated hypertensives
- rs587168 allele carriers
- not on more than two anti-hypertensives
- normal renal, metabolic, electrolyte, and CBC laboratory tests
- self-identified Black race
- age \>17 yrs.
Exclusion
- known cardiac disease other than HTN
- renal, circulatory or neurologic diseases
- diabetes
- smoking
- secondary HTN as indicated by history, physical examination or screening blood and urine tests
- smoking
- any drug therapy, except for anti-hypertensives and stable thyroid medication replacement
Key Trial Info
Start Date :
February 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04840342
Start Date
February 3 2022
End Date
June 1 2026
Last Update
November 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's
Boston, Massachusetts, United States, 02115